Advances in Targeted Therapy for Malignant Pleural Mesothelioma
10.3779/j.issn.1009-3419.2024.102.18
- VernacularTitle:恶性胸膜间皮瘤靶向治疗的研究进展
- Author:
FU FEN
1
;
ZHANG YANG
;
SHEN HONG
Author Information
1. 210011 南京,南京医科大学第二附属医院呼吸与危重症医学科
- Keywords:
Malignant pleural mesothelioma;
Gene mutation;
Epigenetics;
Signaling proteins;
Targeted therapy
- From:
Chinese Journal of Lung Cancer
2024;27(5):391-398
- CountryChina
- Language:Chinese
-
Abstract:
Malignant pleural mesothelioma(MPM)is a rare cancer with high malignancy and aggressiveness on the pleural,caused by the following risk factors including asbestos inhalation,genetic factors,and genetic mutation.The pres-ent chemotherapy,antiangiogenic therapy,and immunotherapy methods are ineffective and the survival time of patients is very short.There is an urgent need to find potential therapeutic targets for MPM.At present,it has been found the following types of targets:gene mutation targets such as BRCA associated protein 1(BAP1)and cyclin-dependent kinase 2A(CDKN2A);epigenetic targets such as lysine(K)-specific demethylase 4A(KDM4A)and lysine-specific demethylase 1(LSD1),and signal protein targets such as glucose-regulated protein 78(GRP78)and signal transducer and activator of transcription 3(STAT3).So far,available clinical trials include phase Ⅱ clinical trials of histone methyltransferase inhibitor Tazemetostat,poly(ADP-ribose)polymerase(PARP)inhibitor Rucaparib and cyclin-dependent kinases 4 and 6(CDK4/6)inhibitor Abemaciclib,as well as phase Ⅰ clinical trials of mesothelin-targeting chimeric antigen receptor T-cell immunotherapy(CAR-T)cell injection in the thoracic cavity and TEA domain family member(TEAD)inhibitor VT3989 and IK-930,and the results of these trials have showed certain clinical efficacy.
